![]() |
4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride |
---|---|
Trade Name | |
Orphan Indication | Fibrodysplasia ossificans progressiva |
USA Market Approval | USA |
USA Designation Date | 2013-04-15 00:00:00 |
Sponsor | La Jolla Pharmaceutical Company, Inc.;10182 Telesis Court, Suite 600;San Diego, California, 92121 |